Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Differentiated Thyroid Gland Carcinoma”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Very early researchLooking for participantsNCT06898437
What this trial is testing

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Not applicableStudy completedNCT02303444
What this trial is testing

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Who this might be right for
Thyroid Neoplasms
Bayer 667
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544111
What this trial is testing

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid Cancer+4 more
Memorial Sloan Kettering Cancer Center 19
Not applicableStudy completedNCT03191643
What this trial is testing

PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 16
Early research (Phase 1)Active Not RecruitingNCT04420754
What this trial is testing

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
AffyImmune Therapeutics, Inc. 70
Large-scale testing (Phase 3)Ended earlyNCT03602495
What this trial is testing

Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 204
Testing effectiveness (Phase 2)Study completedNCT01813136
What this trial is testing

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Centre Leon Berard 168
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06359847
What this trial is testing

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Testing effectiveness (Phase 2)Study completedNCT05660954
What this trial is testing

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Who this might be right for
Differentiated Thyroid Cancer
Grupo Espanol de Tumores Neuroendocrinos 41
Post-approval studies (Phase 4)Study completedNCT03573960
What this trial is testing

Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Eisai Pharmaceuticals India Pvt. Ltd 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)UnknownNCT02586337
What this trial is testing

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Who this might be right for
Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 113
Testing effectiveness (Phase 2)Study completedNCT02390934
What this trial is testing

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

Who this might be right for
Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Testing effectiveness (Phase 2)Study completedNCT01208051
What this trial is testing

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Hurthle Cell Carcinoma+2 more
National Cancer Institute (NCI) 127
Testing effectiveness (Phase 2)Looking for participantsNCT03099356
What this trial is testing

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Who this might be right for
Metastatic Thyroid Cancer
University of Michigan Rogel Cancer Center 22
Load More Results